Tibet Aim Pharm Inc - Asset Resilience Ratio
Tibet Aim Pharm Inc (002826) has an Asset Resilience Ratio of 18.13% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002826 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how Tibet Aim Pharm Inc's Asset Resilience Ratio has changed over time. See net asset quality index of Tibet Aim Pharm Inc to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tibet Aim Pharm Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002826 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥200.00 Million | 18.13% |
| Total Liquid Assets | CN¥200.00 Million | 18.13% |
Asset Resilience Insights
- Good Liquidity Position: Tibet Aim Pharm Inc maintains a healthy 18.13% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Tibet Aim Pharm Inc Industry Peers by Asset Resilience Ratio
Compare Tibet Aim Pharm Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Tibet Aim Pharm Inc (2014–2023)
The table below shows the annual Asset Resilience Ratio data for Tibet Aim Pharm Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | CN¥-2.00 ≈ $-0.29 |
CN¥927.74 Million ≈ $135.76 Million |
-3.59pp |
| 2019-12-31 | 3.59% | CN¥30.00 Million ≈ $4.39 Million |
CN¥835.41 Million ≈ $122.25 Million |
+3.73pp |
| 2015-12-31 | -0.14% | CN¥-570.74K ≈ $-83.52K |
CN¥397.70 Million ≈ $58.20 Million |
-0.96pp |
| 2014-12-31 | 0.82% | CN¥2.20 Million ≈ $321.93K |
CN¥268.42 Million ≈ $39.28 Million |
-- |
About Tibet Aim Pharm Inc
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company's products include Miglitol tablets for diabetes; ethnic medicine products, suitable for treating breast lobular hyperplasia, uterine fibroids, and ovarian cysts; gynecology and obstetrics; and NalMefene hydrochloride injection for various acute poisoning, such as alcoh… Read more